Al Khodor Souhaila, Reichert Bernd, Shatat Ibrahim F
Immunology, Inflammation and Metabolism, Division of Translational Medicine, SIDRA Medical and Research Center, Doha, Qatar.
Division of Neonatology, SIDRA Medical and Research Center, Doha, Qatar.
Front Pediatr. 2017 Jun 19;5:138. doi: 10.3389/fped.2017.00138. eCollection 2017.
The surfaces of the human body are heavily populated by a highly diverse microbial ecosystem termed the microbiota. The largest and richest among these highly heterogeneous populations of microbes is the gut microbiota. The collection of microbes and their genes, called the microbiome, has been studied intensely through the past few years using novel metagenomics, metatranscriptomics, and metabolomics approaches. This has enhanced our understanding of how the microbiome affects our metabolic, immunologic, neurologic, and endocrine homeostasis. Hypertension is a leading cause of cardiovascular disease worldwide; it contributes to stroke, heart disease, kidney failure, premature death, and disability. Recently, studies in humans and animals have shown that alterations in microbiota and its metabolites are associated with hypertension and atherosclerosis. In this review, we compile the recent findings and hypotheses describing the interplay between the microbiome and blood pressure, and we highlight some prospects by which utilization of microbiome-related techniques may be incorporated to better understand the pathophysiology and treatment of hypertension.
人体表面密集分布着一个高度多样化的微生物生态系统，称为微生物群。在这些高度异质的微生物群体中，数量最多、种类最丰富的是肠道微生物群。微生物及其基因的集合称为微生物组，在过去几年中，人们使用新的宏基因组学、宏转录组学和代谢组学方法对其进行了深入研究。这加深了我们对微生物组如何影响我们的代谢、免疫、神经和内分泌稳态的理解。高血压是全球心血管疾病的主要原因；它会导致中风、心脏病、肾衰竭、过早死亡和残疾。最近，人类和动物研究表明，微生物群及其代谢产物的改变与高血压和动脉粥样硬化有关。在这篇综述中，我们汇总了描述微生物组与血压之间相互作用的最新发现和假说，并强调了一些利用微生物组相关技术更好地理解高血压病理生理学和治疗方法的前景。
